Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer have?
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer has 858 citations in the OpenAlex counts ScholarIQ stores.
When was Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer published?
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer has 2019 year in the ScholarIQ index.
What is the open-access status of Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer?
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer has closed oa status in the ScholarIQ index.
What is the DOI of Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer?
The DOI for Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer is on the source record.
What is the PMID of Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer?
The PMID for Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer is on the source record.
What is the OpenAlex record for Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer?
The OpenAlex for Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer is on the source record.